{"slideshow_credits": null, "snippet": "But the market capitalization of Actelion, a Swiss drug maker, is high, so Johnson & Johnson would have to cut costs to make a deal work....", "abstract": null, "section_name": "Business Day", "print_page": null, "document_type": "article", "byline": {"person": [{"firstname": "Neil", "role": "reported", "lastname": "UNMACK", "rank": 1, "organization": ""}], "original": "By NEIL UNMACK"}, "web_url": "http://www.nytimes.com/2016/11/25/business/dealbook/johnson-johnson-actelion.html", "lead_paragraph": "But the market capitalization of Actelion, a Swiss drug maker, is high, so Johnson & Johnson would have to cut costs to make a deal work.", "headline": {"main": "Johnson & Johnson Has Its Eye on Actelion", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "_id": "5838acd37c459f2525d0e5fb", "word_count": "425", "multimedia": [], "pub_date": "2016-11-25T21:22:24+0000", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Actelion Pharmaceuticals Ltd", "is_major": "N", "rank": "1"}, {"name": "organizations", "value": "Johnson & Johnson", "is_major": "N", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}